Genizon pockets $31M CAD in fifth round
Free newsletter via e-mail
Tools
Canada's Genizon BioSciences has garnered $31 million Canadian in its fifth round of financing. The lead investor is BTF B.V. of Haarlem, The Netherlands, which specializes in late-stage biotech companies.
"Genizon's outstanding DNA resources and a platform that is applicable to many stages of drug development make a compelling investment case," said Jan Mellegers, CEO of BTF. "The company has impressed us with its ability to not only discover many genes in each disease, but also to assemble these into GeneMaps that lead to new drug targets and biomarkers."
- here's the release
ALSO: ZyGem says it has closed its first round of financing. Release
Related Article:
Pfizer inks genetic license with Genizon. Report
SHARE
WITH: